Cytotherapy

Papers
(The H4-Index of Cytotherapy is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)
ArticleCitations
Subscription information78
Aims and Scope62
Editorial Board42
Immunotherapy: B7H3-CAR NK CELLS AND DNR CO-TRANSDUCED NK SHOWS MAINTAIN THEIR POTENCY AGAINST TGF-B MEDIATED IMMUNE SUPPRESSION41
Immunotherapy: MULTI-CENTER GAMMA-DELTA T CELL CLINICAL TRIAL PRODUCT IDENTIFICATION USING NEW PRODUCT ATTRIBUTE AND NEW CODES FOR ISBT 128 LABELING39
Mesenchymal Stem/Stromal Cells: HUMAN MSCS REDUCE INFLAMMATION AND PROMOTE REPAIR IN SEVERE HOUSE DIST MITE INDUCED ALLERGIC AIRWAY DISEASE DRIVEN BY MACROPHAGE MIGRATION INHIBITORY FACTOR36
Embryonic, Organ and Other Tissue Specific Stem Cells: EXPLORING THE ANTI-TUMOR EFFECTS OF HUMAN WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELL SECRETOME ON PANCREATIC DUCTAL ADENOCARCINOMA CELLS IN CO34
Exosomes/EVs: Late Breaking Abstract: EFFECTS OF AMNIOTIC FLUID DERIVED EXTRACELLULAR VESICLE BIOLOGIC ON T CELL PROLIFERATION AND ACTIVATION33
Immunotherapy: TARGETING EWING SARCOMA (ES), OSTEOSARCOMA (OS) AND NEUROBLASTOMA (NB) WITH ANTI-MCAM CHIMERIC ANTIGEN RECEPTOR (CAR) MODIFIED NATURAL KILLER (NK) CELLS32
CONSTRUCTION OF DEAD-CAS9 MACHINERY FOR ACTIVATION OF ENDOGENOUS NEUROPROTECTIVE TRANSCRIPTION FACTOR MAX IN VITRO32
iPSC: ENGINEERING 3D MICRO-COMPARTMENTS FOR HIGHLY EFFICIENT AND SCALE-INDEPENDENT EXPANSION OF HUMAN PLURIPOTENT STEM CELLS IN BIOREACTORS29
Process Development and Manufacturing: CRYOPRESERVATION METHOD OPTIMIZATION FOR PLACE-OF-CARE MANUFACTURING OF A FIRST IN HUMAN TRI-SPECIFIC CAR T-CELL THERAPY PRODUCT FOR LYMPHOID MALIGNANCIES28
Immunotherapy: EXPANSION AND PROCESSING OF A CLINICALLY RELEVANT NUMBER OF NK CELLS28
Process Development and Manufacturing: VALIDATION OF THE MANUFACTURING OF AUTOLOGOUS MUC-1 ACTIVATED T CELLS FOR A PHASE I DOSE ESCALATION TRIAL FOR PATIENTS WITH MULTIPLE MYELOMA27
GENERATION OF HUMAN INDUCED PLURIPOTENT STEM CELL LINES DERIVED FROM TWO BRAZILIAN PATIENTS WITH HUTCHINSON-GILFORD PROGERIA SYNDROME CARRYING C.1824 C>T MUTATION27
THERAPEUTIC BENEFIT OF HUMAN WHARTON’S JELLY MESENCHYMAL STROMAL CELLS IN A MOUSE MODEL OF AMYOTROPHIC LATERAL SCLEROSIS27
GENERATION AND OPTIMIZATION OF ANTI-CD19 CAR-T CELL FOR LEUKEMIA IMMUNOTHERAPY26
Mesenchymal Stem/Stromal Cells: HYPERINFLAMMATION AND IMMUNE CELL DYSREGULATION IN C7 HYPOMORPHIC MOUSE MODEL OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA: IMMUNE AND INFLAMMATION MODULATION BY HUMAN25
Process Development and Manufacturing: CAR-T CELLS MANUFACTURED VIA POSITIVE AND NEGATIVE IMMUNOMAGNETIC T CELL SELECTION SHOW DIFFERENT TUMOR KILLING RATES, CYTOKINE PROFILES, AND γδ T CELL OUTPUT25
Tissue Engineering: AUTOLOGOUS 3D NEURAL IMPLANTS FOR SPINAL CORD INJURY24
Mesenchymal Stem/Stromal Cells: ICE RECRYSTALLIZATION INHIBITOR INCREASES POST-THAW FUNCTIONAL CAPACITY OF BONE MARROW AND UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS24
Process Development and Manufacturing: IMPROVED DOWNSTREAM VIRUS PURIFICATION YIELD USING EXCIPIENT-GRADE RECOMBINANT ALBUMIN, EXBUMIN24
Hematopoietic Stem/Progenitor Cells and Engineering: HUMAN UMBILICAL CORD BLOOD DERIVED CELL THERAPY PRODUCT, DUOC-01, PROMOTES REMYELINATION BY DRIVING THE DIFFERENTIATION OF OPC23
Process Development and Manufacturing: ONE YEAR FROM VECTOR TO BEDSIDE: RAMPING UP A SUCCESSFUL IN-HOUSE CAR T-CELL MANUFACTURING PROGRAM USING A NOVEL TRI-SPECIFIC CAR T-CELL THERAPY FOR LYMPHOID MAL23
Immunotherapy: APPLICATIONS OF IMMUNE PROFILING: QUANTITATIVE PHENOTYPIC ANALYSIS OF ALS PATIENTS RECEIVING MSC THERAPY23
Process Development and Manufacturing: A NEEDLE-BASED AUTOSAMPLER FOR BIOREACTOR CELL MEDIA COLLECTION23
Mesenchymal Stem/Stromal Cells: SUBCUTANEOUS DELIVERY OF ALLOGENEIC INTERFERON-γ LICENSED BONE MARROW DERIVED MESENCHYMAL STROMAL CELL (IFN-γ MSC) FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY (TBI)23
0.10198283195496